CAL
REGN icon

Capital Analysts LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Analysts LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$405K Buy
650
+130
+25% +$88.5K 0.01% 533
2026
Q1 		$402K Sell
520
-2
-0.4% -$1.53K 0.01% 494
2025
Q4 		$403K Sell
522
-83
-14% -$56.4K 0.01% 465
2025
Q3 		$340K Buy
605
+192
+46% +$109K 0.01% 487
2025
Q2 		$217K Hold
413
– – 0.01% 537
2025
Q1 		$262K Buy
413
+16
+4% +$11K 0.01% 480
2024
Q4 		$283K Buy
397
+69
+21% +$57.9K 0.01% 419
2024
Q3 		$345K Sell
328
-7
-2% -$7.79K 0.01% 379
2024
Q2 		$352K Buy
335
+40
+14% +$38.8K 0.02% 379
2024
Q1 		$284K Buy
295
+1
+0.3% +$951 0.01% 386
2023
Q4 		$258K Sell
294
-1
-0.3% -$823 0.01% 391
2023
Q3 		$243K Buy
295
+12
+4% +$9.43K 0.01% 373
2023
Q2 		$203K Sell
283
-8
-3% -$6.17K 0.01% 376
2023
Q1 		$239K Sell
291
-23
-7% -$17.3K 0.01% 359
2022
Q4 		$227K Sell
314
-29
-8% -$21.4K 0.01% 382
2022
Q3 		$236K Sell
343
-35
-9% -$22K 0.02% 337
2022
Q2 		$223K Buy
378
+12
+3% +$7.8K 0.02% 333
2022
Q1 		$256K Sell
366
-97
-21% -$61.4K 0.02% 319
2021
Q4 		$292K Buy
463
+17
+4% +$10.5K 0.02% 309
2021
Q3 		$270K Buy
446
+46
+12% +$28.6K 0.02% 311
2021
Q2 		$223K Sell
400
-2
-0.5% -$1.01K 0.02% 326
2021
Q1 		$190K Buy
402
+27
+7% +$13.1K 0.01% 348
2020
Q4 		$181K Sell
375
-440
-54% -$238K 0.02% 252
2020
Q3 		$456K Buy
815
+380
+87% +$230K 0.04% 198
2020
Q2 		$271K Sell
435
-55
-11% -$31.2K 0.03% 208
2020
Q1 		$239K Buy
490
+55
+13% +$22.7K 0.03% 195
2019
Q4 		$163K Buy
+435
New +$146K 0.02% 250

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital Analysts LLC's REGN Position: Q2 2026 in Review

Capital Analysts LLC increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q2 2026, buying an estimated $88.5K and bringing the position to 650 shares worth $405K. The position accounts for 0.01% of the portfolio, ranked #533.

Capital Analysts LLC first reported a position in REGN in Q4 2019 and has held it in 27 quarters since. The position peaked at $456K in Q3 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital Analysts LLC held 650 shares of Regeneron Pharmaceuticals worth $405K as of Q2 2026.
  • Capital Analysts LLC bought 130 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $88.5K.
  • Regeneron Pharmaceuticals made up 0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #533 holding.
  • Capital Analysts LLC first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Capital Analysts LLC's Regeneron Pharmaceuticals position peaked at $456K in Q3 2020.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.